TY - JOUR
T1 - Visceral Pain in Preterm Infants with Necrotizing Enterocolitis
T2 - Underlying Mechanisms and Implications for Treatment
AU - ten Barge, Judith A.
AU - van den Bosch, Gerbrich E.
AU - Slater, Rebeccah
AU - van den Hoogen, Nynke J.
AU - Reiss, Irwin K.M.
AU - Simons, Sinno H.P.
N1 - Publisher Copyright: © The Author(s) 2025.
PY - 2025/1/3
Y1 - 2025/1/3
N2 - Necrotizing enterocolitis (NEC) is a relatively rare but very severe gastrointestinal disease primarily affecting very preterm infants. NEC is characterized by excessive inflammation and ischemia in the intestines, and is associated with prolonged, severe visceral pain. Despite its recognition as a highly painful disease, current pain management for NEC is often inadequate, and research on optimal analgesic therapy for these patients is lacking. Insight into the mechanisms underlying intestinal pain in infants with NEC—visceral pain—could help identify the most effective analgesics for these vulnerable patients. Therefore, this comprehensive review aims to provide an overview of visceral nociception, including transduction, transmission, modulation, and experience, and discuss the implications for analgesic therapy in preterm infants with NEC. The transmission of visceral pain differs from that of somatic pain, contributing to the diffuse nature of visceral pain. Studies evaluating the effectiveness of analgesics for treating visceral pain in infants are scarce. However, research in visceral pain models highlights agents that may be particularly effective for treating visceral pain based on their mechanisms of action. Further research is necessary to determine whether agents that have shown promise for treating visceral pain in preclinical studies and adults are effective in infants with NEC as well.
AB - Necrotizing enterocolitis (NEC) is a relatively rare but very severe gastrointestinal disease primarily affecting very preterm infants. NEC is characterized by excessive inflammation and ischemia in the intestines, and is associated with prolonged, severe visceral pain. Despite its recognition as a highly painful disease, current pain management for NEC is often inadequate, and research on optimal analgesic therapy for these patients is lacking. Insight into the mechanisms underlying intestinal pain in infants with NEC—visceral pain—could help identify the most effective analgesics for these vulnerable patients. Therefore, this comprehensive review aims to provide an overview of visceral nociception, including transduction, transmission, modulation, and experience, and discuss the implications for analgesic therapy in preterm infants with NEC. The transmission of visceral pain differs from that of somatic pain, contributing to the diffuse nature of visceral pain. Studies evaluating the effectiveness of analgesics for treating visceral pain in infants are scarce. However, research in visceral pain models highlights agents that may be particularly effective for treating visceral pain based on their mechanisms of action. Further research is necessary to determine whether agents that have shown promise for treating visceral pain in preclinical studies and adults are effective in infants with NEC as well.
UR - http://www.scopus.com/inward/record.url?scp=85213854436&partnerID=8YFLogxK
U2 - 10.1007/s40272-024-00676-0
DO - 10.1007/s40272-024-00676-0
M3 - Review article
C2 - 39752054
AN - SCOPUS:85213854436
SN - 1174-5878
VL - 27
SP - 201
EP - 220
JO - Pediatric Drugs
JF - Pediatric Drugs
IS - 2
M1 - e3
ER -